AtriCure (ATRC) Price to Sales (2010 - 2026)

AtriCure (ATRC) has reported Price to Sales for 17 consecutive years, with 9.27 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Price to Sales fell 22.54% year-over-year to 9.27 in Q2 2026; TTM through Jun 2026 was 2.5, a 23.29% decrease from a year earlier, with the FY2025 full-year figure at 3.69, up 14.81% from the prior year.
• Price to Sales was 9.27 for Q2 2026 at AtriCure, down from 10.23 in the prior quarter.
• Over five years, Price to Sales peaked at 40.74 in Q1 2022 and troughed at 9.27 in Q2 2026.
• A 5-year average of 17.11 and a median of 13.77 in 2024 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales sank 58.83% in 2024 and grew 25.45% in 2025, its largest moves.
• Over 5 years, Price to Sales stood at 23.48 in 2022, then plunged by 32.18% to 15.92 in 2023, then retreated by 24.52% to 12.02 in 2024, then rose by 16.67% to 14.02 in 2025, then tumbled by 33.91% to 9.27 in 2026.
• The last three Price to Sales figures came in at 9.27 (Q2 2026), 10.23 (Q1 2026), and 14.02 (Q4 2025), per Business Quant data.